Compare CoreWeave (CRWV) vs Eli Lilly And Co (LLY) Price & Performance

CRWV trades at $82.08, down 7.2% amid a broader AI stock sell-off. The technical picture is bearish, with price below key resistance levels. Fundamentally, the company shows strong revenue growth but deep losses, with a net income margin of -25.4% in 2026. A massive $104 billion backlog signals high demand, yet expansion requires significant debt and equity financing, increasing financial risk.

The outlook is polarized: high growth potential from AI infrastructure demand contrasts with substantial execution and financial risks. Analyst consensus is bullish with a $147.57 price target, but investors face volatility from debt-funded expansion and competitive pressures. The stock's trajectory hinges on converting its backlog to profitable revenue.

Eli Lilly (LLY) trades at $1,179.27, down 0.79% on the day, with a bullish technical outlook and strong fundamental momentum. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 expectation. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing its market leadership.

The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include competitive pressures in the obesity drug market and execution challenges in scaling production. With a consensus price target of $1,350, representing ~14% upside, the stock offers growth potential but requires monitoring of pipeline progress and market dynamics.